LASERTEAM
Medical laser technology

The Future

# of skin rejuvenation laser treatment

Epicare The breakthrough
Ablative Q Switch Thulium Laser

Meet Epicare

Our Ablative Q-Switch
Thulium Laser -
The only laser of its kind

Narrow Beam, Bigger Benefit for Clinics
With Ultra Narrow Spots, its smallest precision beam and depth control, it delivers **less pain, less downtime, and more cost-effective solutions**.

The non-invasive aesthetic treatment market is booming

Here's why



Zoom Effect

Consumers are spending more time **looking at their reflections** - video calls have permanently changed how we view ourselves.

Shift away

Aesthetic lasers are quickly replacing plastic surgery for their quick recovery and minimal discomfort.

Male Clients

Aesthetic procedures are in high demand among men. Aesthetic medicine offers subtle tweaks instead of dramatic procedures.

*** https://www.visionresearchreports.com/non-invasive-aesthetic-treatment-market/39012

For non-invasive treatments,

Lasers are leading the way

Aesthetic laser treatments are among the **most lucrative services** in the non-invasive sector

There are **5 major issues** with the current laser treatments

5 major issues with current lasers

1

OVERSATURATED

Me too options

2

OVERSPECIALIZED

Specialized lasers for each problem

- Wrinkles
- Scars
- Pigmentation-reducing
- Cost-effectiveness

5 major issues with current lasers

3

MULTIPLE SIDE EFFECTS

Side Effects

- Scarring
- Burns
- Pain
- Infection
- Hypopigmentation
- PIH (Post Inflammatory Hyperpigmentation)

5 major issues with current lasers

4

BARRIERS FOR **PEOPLE OF COLOR**

50%

of potential patients of color can't receive best treatment

5 major issues with current lasers

5

LONG DOWNTIME -
UP TO 2 WEEKS!

Other technologies with milder results

- Fractional ablation
- Fractional non-ablation
- RF
- Micro-needling
- Ultrasound

Introducing

Epicare's Breakthrough Technology

One Laser. Endless Solutions.

CO2 Technologies

Long Pulse

LASERTEAM



- Many fast and high power laser pulses
- On the same spot.
- With or without peripheral thermal effect

300% coagulation



CO2 Technologies



- The ability to achieve a wider coagulation density, while performing less epidermis damage

LASERTEAM

Dermis pigmentation
Current technology:
Non-ablative Thulium 1940 nm

Drug delivery
Current technology: CO2

Wrinkles, Skin rejuvenation and Scars
Current technology:
CO2, Er:Yag

Epidermis pigmentation
Current technology: 1927nm, 1940nm, long pulse duration Tm

Outshines the competition

Max results. Min discomfort. Min downtime.

Laser Machine	Epicare	Er-Yag	CO2
Coagulation BETTER +	Hemostasis to 300% Controlled while lase	From 0+ to <<30%	30%
Spot size SMALLER +	40µm Downtime less than 4 days	170µm	120µm
Max power	2 Watt	10Watt	60Watt

Histological comparison

Actual Coagulation width

80 mJ

120 mJ

160 mJ



High coagulation microcolumns at various energies

300% coagulation

Ultra Narrow Spots

LASERTEAM

CO2 Technologies



A side-by-side comparison between our low-frequency operation and the CO2RE ablation with the same scale

Proven efficacy in published studies

Lasers in Surgery and Medicine

PRECLINICAL STUDY OPEN ACCESS

Evaluation of a Novel Ablative 1940 nm Pulsed Laser for Skin Rejuvenation

Yoav Gronovich[1] | Yaniv Raderman[1] | Ronen Toledano[1] | Rotem Nahear[2] | Neria Suliman[2] | Alon Shacham[2] | David Fridman[2] | Salman Noach[2,3]

[1]Plastic and Reconstructive Surgery Department, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel | [2]Laser Team Medical Ltd, Jerusalem, Israel | [3]Department of Applied Physics, Electro-Optics Engineering Faculty, Jerusalem College of Technology, Jerusalem, Israel

Correspondence: Yoav Gronovich (yoavgg@gmail.com)

Received: 18 February 2024 | **Revised:** 29 May 2024 | **Accepted:** 1 June 2024

Keywords: 1940 nm | ablative | laser | resurfacing | skin rejuvenation

Our team is a collection of engineers and medical doctors who understand the market and its needs

LTM CEO

Pini Ben Elazar, MBA

Veteran CEO in healthcare, led Mor Research applications, TTO of Clalit for 20 years.

Founded more than 80 startup companies.

CTO & CO-Founder

Prof. Salman Noach

Veteran CTO with 25 years of experience, inventor and founder of the 2µm solid-state laser lab at JCT, a faculty member at the physics department at JCT.

CMO

Dr. David J. Friedman, MD.

Expert in non-surgical aesthetic and laser dermatology, with extensive experience in clinical trials and training.

US Board Certified Dermatologist in the US and Israel. Former Assistant Professor at Brown. Medical Director of Candela Israel and Physician Trainer at Allergan Israel.

COO

Avi Mendelson, B.SC

Over 25 years of senior management in R&D and operations within startup and leading Medical Device companies (Lumenis, Candela)

Scientific advisory board

Dr. Jeffrey S. Dover, MD

A former Associate Professor of Dermatology at Harvard Medical School, he is the author of over 550 scientific publications and has co-authored and edited over 55 textbooks. Dr. Dover is the past president of the American Society for Lasers in Medicine and Surgery, the American Society for Dermatologic Surgery, and the New England Dermatology Society.

Dr. Sarit Cohen, MD

Head of the Israeli Center of Facial Sculpting, specializes in invasive and minimally invasive facial aesthetic procedures. Board-certified in plastic, reconstructive, and aesthetic surgery, she is a consultant for leading aesthetic companies and has published extensively on facial and body procedures.

Paul M. Friedman, MD

Director of Dermatology & Laser Surgery Center in Houston. Board-certified in dermatology, he trained at NYU and completed a fellowship in dermatologic and Mohs surgery. He is recognized globally for his advancements in dermatologic laser treatments.

Dr. Yakir Levin, MD, PhD

An Assistant Professor of Dermatology at Harvard Medical School and is a physician-scientist at the Massachusetts General Hospital. He maintains an active clinical practice at MGH's acclaimed Laser and Cosmetic Center and a significant research portfolio at its world-renowned Wellman Center for Photomedicine. He subspecializes in aesthetic dermatology and in the treatment of disfiguring birthmarks in children and conducts human and preclinical research studies geared toward improving these treatments

Regulatory pathway to market success

Executed by Hogan Lovells US LLP and BioVision Ltd.

Traditional 510(k) premarket submission

Q1 2026 — Estimated time for the submission date

Q4 2026 — Estimated time to receive FDA clearance

Pre-Submission meeting, to obtain the FDA's early feedback on the proposed regulatory strategy:

1. **Indications for Use:** The Epicare System is indicated for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin for the treatment of facial wrinkles.

2. **Predicate and Reference devices:**
   - Primary Predicate: LASEMD Laser System (K171009)
   - Reference Device: Syneron Medical Ltd. CO2RE (K151655)

3. **GLP Animal Study:** evaluation of the Safety and Efficacy of the Epicare System in Performing Fractional Skin Ablation in a Swine Model

4. **Clinical Study:** A Prospective, Interventional, Evaluator-Blinded, Single-Center Study for the Assessment of the Safety and Efficacy of Epicare for the Treatment of Periorbital Wrinkles

5. **Estimated time** for the submission of the official pre-submission to the FDA – Q2 2025

Granted Patents

2µm Q-SWITCH Technology

Enable to achieve high energy pulses in nanosecond regime

Status: **GRANTED**
Filing date: April 2, 2018

Granted US Patent No. 10,978,850

1.7 to 3µm Tunable Q-Switch Technology

Enable to achieve different wavelengths of high energy pulses in nanosecond regime with a tunable spectral range of at least 20 nm;

Status: **GRANTED**
Filing date: May 22, 2019

Granted US Patent No. 11,791,602

Pending Patents

Precise control over laser medical treatments

Enable to achieve Different controlled depth and different controlled coagulation width on a human tissue (skin)

Status: **PENDING -** National phase
(US; China; European patent office; Korea)

Filing date: Aug 29, 2023

Pending PCT Application No. PCT/IL2023/050915

Special laser pulse scanning to achieve fast treatment

Enable to achieve ultra fast treatment on treated area

Status: **PENDING PCT**

Filing date: Jan 25, 2024

Pending PCT Application No. PCT/IL2024/050100

Laser-focused on growing our business with

Additional applications and markets

Gynecology

Vaginal rejuvenation and more

Ophthalmology

ENT

Middle ear surgery, stapedotomy

Laryngeal cancer, and more

Brain Surgery

Drug Delivery

Enhanced trans dermal drug delivery

Gantt Chart (9/24 – 6/27)



An Innovation Authority grant is a good start, now we're ready to scale...

In September 2024, we received a grant that supports us for the next 2 years by The Israel Innovation Authority

רשות החדשנות
Israel Innovation Authority

With your investment, we will be able to scale this groundbreaking technology and redefine the future of the aesthetic laser market.

Invest in Epicare

The game-changing innovation the laser market has been waiting for!

Thank You!

pinib@lasertm.com

LASERTEAM
Medical laser technology